Agios Pharmaceuticals Inc (AGIO) volume exceeds 0.78 million: A new investment opportunity for investors

Agios Pharmaceuticals Inc (NASDAQ: AGIO) kicked off on Friday, up 4.53% from the previous trading day, before settling in for the closing price of $58.97. Over the past 52 weeks, AGIO has traded in a range of $20.96-$62.58.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 2.66%. While this was happening, its average annual earnings per share was recorded 281.41%. With a float of $55.13 million, this company’s outstanding shares have now reached $57.02 million.

Considering the fact that the conglomerate employs 383 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 76.16%, operating margin of -1238.1%, and the pretax margin is 2212.98%.

Agios Pharmaceuticals Inc (AGIO) Breakdown of a Key Holders of the stock

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Agios Pharmaceuticals Inc is 3.32%, while institutional ownership is 104.92%. The most recent insider transaction that took place on Nov 08 ’24, was worth 43,301. In this transaction Principal Accounting Officer of this company sold 772 shares at a rate of $56.09, taking the stock ownership to the 813 shares. Before that another transaction happened on Nov 08 ’24, when Company’s Director sold 10,000 for $58.19, making the entire transaction worth $581,911. This insider now owns 7,992 shares in total.

Agios Pharmaceuticals Inc (AGIO) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around 281.41% per share during the next fiscal year.

Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators

Take a look at Agios Pharmaceuticals Inc’s (AGIO) current performance indicators. Last quarter, stock had a quick ratio of 8.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 111.79.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.37, a number that is poised to hit -1.68 in the next quarter and is forecasted to reach -6.08 in one year’s time.

Technical Analysis of Agios Pharmaceuticals Inc (AGIO)

Compared to the last year’s volume of 0.69 million, its volume of 0.62 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 70.57%. Additionally, its Average True Range was 2.45.

During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 95.85%, which indicates a significant increase from 92.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.95% in the past 14 days, which was lower than the 42.11% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $49.67, while its 200-day Moving Average is $41.74. Nevertheless, the first resistance level for the watch stands at $63.03 in the near term. At $64.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $66.39. If the price goes on to break the first support level at $59.67, it is likely to go to the next support level at $57.70. Now, if the price goes above the second support level, the third support stands at $56.31.

Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats

The company with the Market Capitalisation of 3.67 billion has total of 57,030K Shares Outstanding. Its annual sales at the moment are 26,820 K in contrast with the sum of -352,090 K annual income. Company’s last quarter sales were recorded 8,960 K and last quarter income was 947,920 K.